HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare Conference
February 16 2021 - 7:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics based on its proprietary
arenavirus platform, today announced that HOOKIPA’s management team
will participate in the upcoming virtual SVB Leerink Global
Healthcare Conference:
- Fireside
Discussion: Thursday, February 25, 2021 at 9:20 AM ET
The live audio webcast of the presentation will
be available within the Investors & Media section of HOOKIPA’s
website at https://ir.hookipapharma.com/events. An archived replay
will be accessible for 30 days following the event.
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics based on its proprietary arenavirus platform
that reprograms the body’s immune system. HOOKIPA’s
proprietary arenavirus-based technologies, non-replicating and
replicating, are designed induce robust antigen-specific
CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral
vectors target antigen presenting cells in vivo to activate the
immune system. Both technologies enable repeat administration to
augment and refresh immune responses. As a
monotherapy, HOOKIPA’s replicating arenavirus technology
has the potential to induce CD8+ T cell response levels previously
not achieved by other immuno-therapy approaches.
HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens, and next-generation antigens. The lead
replicating arenavirus oncology product candidates, HB-201 and
HB-202, are in development for the treatment of Human Papilloma
Virus 16-positive cancers in a Phase 1/2 clinical
trial.
HOOKIPA’s non-replicating
prophylactic cytomegalovirus (CMV) vaccine candidate is
currently in a Phase 2 clinical trial for patients awaiting kidney
transplantation. To expand its infectious disease portfolio,
HOOKIPA entered into a collaboration and licensing agreement with
Gilead Sciences, Inc. to research arenavirus-based functional cures
for HIV and chronic Hepatitis B infections.
Find out more about HOOKIPA online
at www.hookipapharma.com.
For further
information, please contact: |
|
|
|
Media |
|
Investors |
Nina Waibel |
|
Matt Beck |
Senior Director - Communications |
|
Executive Director - Investor Relations |
nina.waibel@hookipapharma.com |
|
matthew.beck@hookipapharma.com |
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024